Elipse Balloon from Allurion Technologies
Boston-based Allurion Technologies has raised $27 million in Series C funding to commercialize its intragastric balloon device. Contributors included current investor Romulus Capital, along with Cogepa Investments and IDO Investments.
“The funding…
Source: medcitynews.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
